Onset and Duration of Clinical Effect of IPX066 in Advanced Parkinson's Disease

被引：0

|

作者：

Ellenbogen, Aaron

Hauser, Robert A.

Modi, Nishit B.

Hsu, Ann

Khanna, Sarita

Gupta, Suneel

机构：

来源：

ANNALS OF NEUROLOGY | 2015年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S419

引用

收藏

页码：S48 / S48

页数：1

相关论文

共 50 条

[31] Safety analysis by higher and lower total daily dose of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
Hinson, V. K.
Stover, N.
Agarwal, P.
Khanna, S.
Kell, S.
MOVEMENT DISORDERS, 2015, 30 : S90 - S91
[32] Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Motor Fluctuations in Advanced Parkinson's Disease
Ellenbogen, Aaron
Nausieda, Paul
Pourcher, Emmanuelle
Rudzinska, Monika
Kell, Sherron
O'Connell, Martin
Hsu, Ann
Gupta, Suneel
NEUROLOGY, 2013, 80
[33] Conversion of advanced Parkinson's disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations
Gupta, S.
Rubens, R.
Rustay, N.
Khanna, S.
Kell, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 526 - 526
[34] PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMEDIATE-RELEASE CARBIDOPA-LEVODOPA
Rubens, R.
Rustay, N. R.
Khanna, S.
Kell, S.
Gupta, S.
VALUE IN HEALTH, 2015, 18 (03) : A279 - A279
[35] Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Early Parkinson's Disease
Nausieda, Paul
Rudzinska, Monika
Kell, Sherron
O'Connell, Martin
Hsu, Ann
Gupta, Suneel
NEUROLOGY, 2013, 80
[36] Motor function assessment in advanced Parkinson's disease (PD) patients after IPX066 and controlled-release carbidopa-levodopa (CR) using the Unified Parkinson's Disease Rating Scale (UPDRS) and the objective Parkinson's disease measurement (OPDM)
Tetrud, J.
Liang, G.
Ellenbogen, A.
Duker, A.
Hsu, A.
O'Connell, M.
Khanna, S.
Kell, S.
Gupta, S.
MOVEMENT DISORDERS, 2014, 29 : S270 - S270
[37] Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
Cheryl H. Waters
Paul Nausieda
Lyudmila Dzyak
Joerg Spiegel
Monika Rudzinska
Dee E. Silver
Elena S. Tsurkalenko
Sherron Kell
Ann Hsu
Sarita Khanna
Suneel Gupta
CNS Drugs, 2015, 29 : 341 - 350
[38] The effects of gender on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S148 - S148
[39] Comparison of single-dose motor effects of IPX066 to immediate-release carbidopa-levodopa plus entacapone (CLE) in advanced Parkinson's disease (PD) patients
Ellenbogen, A.
Stocchi, F.
Duker, A. P.
Hsu, A.
Khanna, S.
Modi, N.
Rubens, R.
Gupta, S.
MOVEMENT DISORDERS, 2012, 27 : S115 - S116
[40] The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S146 - S147

← 1 2 3 4 5 →